Healthcare
Palvella Therapeutics, Inc.(PVLA)
Live Price
Offline$113.10
+0.42% today
1Y Change
+401.77%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $1.50B
- Revenue Growth
- 0.0%
- EPS Growth
- +52.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Palvella Therapeutics, Inc. (PVLA) is a Healthcare stock with a market cap of $1.50B and listed on NASDAQ. The stock last traded around $113.10 and up 401.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +52.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +52.6%, free cash flow -130.7% with operating margin 0.0% and ROIC -79.7%. Stock Foundry combines PVLA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 7, 2026 with an EPS surprise of -33.3%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +52.6%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | -33.3% | +7.1% | +5.0% | -4.1% |
2026 Mar 31, 2026 | -18.5% | -3.4% | -1.2% | -1.8% |
2025 Nov 11, 2025 | -21.2% | +4.7% | +6.5% | +25.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PVLA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PVLA Max Drawdown
-31.11%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PVLA and SPY.
Company Overview
Palvella Therapeutics, Inc.
NASDAQ Global Market
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
- Leadership
- Wesley H. Kaupinen
- IPO Date
- Jan 2, 2015
- Employees
- 14
- Street Address
- 125 Strafford Avenue
- Mailing
- Wayne, PA, 19087
- Region
- Wayne, PA, US
- Reporting Currency
- USD
- Investor Line
- 484 253 1461
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 51.0
Growth
- Revenue
- 0.0%
- EPS
- +52.6%
- Free Cash Flow
- -130.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -98.1%
- ROIC
- -79.7%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 5.20
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.